Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ULTRAGENYX PHARMACEUTICAL INC.

(RARE)
  Report
Delayed Nasdaq  -  04:00 2022-11-29 pm EST
35.67 USD   +0.76%
11/29Transcript : Ultragenyx Pharmaceutical Inc. Presents at Piper Sandler 34th Annual Healthcare Conference, Nov-29-2022 10:00 AM
CI
11/22Ultragenyx to Present at Piper Sandler Healthcare Conference
GL
11/22Ultragenyx to Present at Piper Sandler Healthcare Conference
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

ULTRAGENYX PHARMACEUTICAL INC. : Change in Directors or Principal Officers (form 8-K)

09/15/2022 | 04:09pm EST

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Amendment to CEO Employment Agreement

On September 9, 2022, the Compensation Committee (the "Committee") of the Board of Directors of Ultragenyx Pharmaceutical Inc. (the "Company") approved entry into Amendment No. 2 (the "CEO Amendment") to the Executive Employment Agreement dated June 15, 2011 between Emil D. Kakkis, M.D., Ph.D., the Company's President and Chief Executive Officer, and the Company (as amended, the "CEO Employment Agreement")

The CEO Amendment provides that, subject to Dr. Kakkis's execution of a release agreement in favor of the Company and other than in situations where termination is For Cause, By Death or By Disability (as each is defined in the CEO Employment Agreement), if the Company terminates the employment of Dr. Kakkis or if Dr. Kakkis terminates his employment with the Company for Good Reason (as defined in the CEO Amendment), Dr. Kakkis will be entitled to receive the following severance benefits: (i) the sum of 24 months of his base salary and his target bonus for the year in which the termination occurs, payable in installments over 24 months; and (ii) reimbursement for monthly COBRA premiums for the 24 month-period following his termination (or, if earlier, until, the date he becomes eligible to receive coverage from another employer), payable on a monthly basis unless Dr. Kakkis loses COBRA eligibility, in which case the Company will pay him a lump sum equal to the COBRA premiums paid in the final month of his eligibility for the number of months remaining in the 24-month period.

In addition, if the qualifying termination occurs on or within 12 months following a Covered Transaction (as defined in the CEO Employment Agreement), in lieu of clause (i) above, Dr. Kakkis would receive a lump sum severance payment equal to the sum of 24 months of Dr. Kakkis's base salary and two times his target bonus for the year in which the termination occurs.

This foregoing is only a summary of certain terms of the CEO Amendment and is qualified in its entirety by the full text of the CEO Amendment, a copy of which the Company intends to file with the Securities and Exchange Commission (the "SEC") as an exhibit to the Company's Quarterly Report on Form 10-Q.

Amendments to Offer Letters

On September 9, 2022, the Committee also approved entry into amendments (the "Offer Letter Amendments") to the existing offer letters with each of Mardi C. Dier, the Company's Chief Financial Officer and Executive Vice President, Camille L. Bedrosian, M.D., the Company's Chief Medical Officer and Executive Vice President, Erik Harris, the Company's Chief Commercial Officer and Executive Vice President, and John R. Pinion II, the Company's Chief Quality Operations Officer and Executive Vice President, Translational Sciences.

The Offer Letter Amendments provide that, where the executive is terminated by the Company without Cause (as defined in the applicable offer letter) and not as a result of the executive's death or disability, or if the executive resigns due to a Constructive Termination (as defined in the applicable offer letter), the executive will be entitled to the following severance benefits: (i) extension of the exercise period applicable to any options to purchase the Company's stock held by the executive at the time of their termination until 12 months from the date of such termination (or, if earlier, until the expiration of the term of the option set forth in the applicable option award agreement), (ii) the sum of 12 months of the executive's base salary and the executive's target bonus for the year in which the termination occurs, payable in installments over 12 months; and (iii) reimbursement for monthly COBRA premiums for the 12 month-period following the executive's termination (or, if earlier, until, the date the executive becomes eligible to receive coverage from another employer or loses COBRA eligibility).Dr. Bedrosian's Offer Letter Amendment also includes accelerated vesting of the unvested equity-based compensation that would have vested in the 12-month period following her qualifying termination.

In addition, if the qualifying termination occurs on or within 18 months (or, for Dr. Bedrosian, within 24 months) following a Covered Transaction (as defined in the Company's 2014 Incentive Plan), the severance benefits that the executive will be entitled to will instead include: (i) accelerated vesting of any unvested equity-based compensation granted to the executive in connection with their employment, (ii) extension of the exercise period applicable to any options to purchase the Company's stock held by the executive at the time of their termination until 12 months from the date of such termination (or, if earlier, until the expiration of the term of the option set forth in the applicable option award agreement), (iii) the sum of 18 months of the executive's base salary and 1.5 times the executive's target bonus for the year in which the termination occurs, payable in installments over 18 months; and (iv) reimbursement for monthly COBRA premiums for the 18 month-period following their termination (or, if earlier, until, the date the executive becomes eligible to receive coverage from another employer or loses COBRA eligibility).

--------------------------------------------------------------------------------

The foregoing is only a summary of certain terms of the Offer Letter Amendments and is qualified in its entirety by the full text of each Offer Letter Amendment, a copy of which the Company intends to file with the SEC as an exhibit to the Company's Quarterly Report on Form 10-Q.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about ULTRAGENYX PHARMACEUTICAL INC.
11/29Transcript : Ultragenyx Pharmaceutical Inc. Presents at Piper Sandler 34th An..
CI
11/22Ultragenyx to Present at Piper Sandler Healthcare Conference
GL
11/22Ultragenyx to Present at Piper Sandler Healthcare Conference
GL
11/21Ultragenyx reports inducement grant under nasdaq listing rule 5635(4)
AQ
11/18Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GL
11/18Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
11/17Transcript : Ultragenyx Pharmaceutical Inc. Presents at 13th Annual Jefferies..
CI
11/15Transcript : Ultragenyx Pharmaceutical Inc. Presents at Stifel 2022 Healthcar..
CI
11/11Ultragenyx Pharmaceutical Chief Financial Officer Mardi Dier to Depart for Private Biop..
MT
11/10Ultragenyx Pharmaceutical Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
More news
Analyst Recommendations on ULTRAGENYX PHARMACEUTICAL INC.
More recommendations
Financials (USD)
Sales 2022 365 M - -
Net income 2022 -705 M - -
Net cash 2022 760 M - -
P/E ratio 2022 -3,57x
Yield 2022 -
Capitalization 2 501 M 2 501 M -
EV / Sales 2022 4,76x
EV / Sales 2023 4,72x
Nbr of Employees 1 119
Free-Float 95,1%
Chart ULTRAGENYX PHARMACEUTICAL INC.
Duration : Period :
Ultragenyx Pharmaceutical Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 35,67 $
Average target price 97,00 $
Spread / Average Target 172%
EPS Revisions
Managers and Directors
Emil D. Kakkis President, Chief Executive Officer & Director
Daniel G. Welch Non-Executive Chairman
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Camille L. Bedrosian Chief Medical Officer & Executive Vice President
Samuel C. Wadsworth Chief Scientific Office
Sector and Competitors
1st jan.Capi. (M$)
ULTRAGENYX PHARMACEUTICAL INC.-57.58%2 501
VERTEX PHARMACEUTICALS44.05%81 199
REGENERON PHARMACEUTICALS, INC.17.41%78 615
BIONTECH SE-36.54%39 760
WUXI APPTEC CO., LTD.-34.05%31 776
GENMAB A/S20.91%28 866